Report overview
Central Nervous System (CNS) Stimulant Drug has its own characteristic mechanism of action on CNS neurones and their associated receptors and nerve terminals.
This report contains market size and forecasts of Central Nervous System (CNS) Stimulant Drugs in global, including the following market information:
Global Central Nervous System (CNS) Stimulant Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Central Nervous System (CNS) Stimulant Drugs Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Central Nervous System (CNS) Stimulant Drugs companies in 2021 (%)
The global Central Nervous System (CNS) Stimulant Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Amphetamine Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Central Nervous System (CNS) Stimulant Drugs include Astellas Pharma, Biogen, Celltech, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck, Novartis and Perdue Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Central Nervous System (CNS) Stimulant Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Central Nervous System (CNS) Stimulant Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Central Nervous System (CNS) Stimulant Drugs Market Segment Percentages, by Type, 2021 (%)
Amphetamine
Cocaine
Caffeine
Others
Global Central Nervous System (CNS) Stimulant Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Central Nervous System (CNS) Stimulant Drugs Market Segment Percentages, by Application, 2021 (%)
Attention Deficit Hyperactivity Disorder (ADHD)
Narcolepsy
Others
Global Central Nervous System (CNS) Stimulant Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Central Nervous System (CNS) Stimulant Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Central Nervous System (CNS) Stimulant Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Central Nervous System (CNS) Stimulant Drugs revenues share in global market, 2021 (%)
Key companies Central Nervous System (CNS) Stimulant Drugs sales in global market, 2017-2022 (Estimated), (MT)
Key companies Central Nervous System (CNS) Stimulant Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Pharma
Biogen
Celltech
Eli Lilly and Company
GlaxoSmithKline
Johnson and Johnson
Merck
Novartis
Perdue Pharma
Pfizer
Roche
Sanofi
Shire
Takeda Pharmaceuticals
Thermo Fisher Scientific
